Itrazol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itrazol

Quick Facts

Characteristic Detail
Drug Class Triazole Antifungal Agent
Primary Use Treat systemic and superficial fungal infections
Mechanism Inhibits fungal ergosterol synthesis

Itraconazole (often sold under the brand name Sporanox, among others) is a synthetic broad-spectrum antifungal medication belonging to the triazole class of antifungals. It is an orally administered drug used to treat various fungal infections, including both systemic (internal) infections and superficial mycoses, such as those affecting the nails (onychomycosis) or skin.

How Itraconazole Works

The primary mechanism of action for Itraconazole is its ability to disrupt the fungal cell membrane. The drug inhibits a specific fungal enzyme called lanosterol 14-alpha-demethylase. By inhibiting this enzyme, Itraconazole prevents the synthesis of ergosterol, which is a vital component necessary for maintaining the structural integrity and function of the fungal cell membrane. This disruption ultimately leads to the death of the fungal cell.

Itraconazole is used for treating serious infections like histoplasmosis, blastomycosis, and aspergillosis, as well as certain forms of candidiasis. Due to its extensive tissue distribution, particularly into keratinous tissues like skin and nails, Itraconazole remains effective for prolonged periods after treatment discontinuation.

Regulatory References

  1. Itraconazole - StatPearls - NIH

What side effects are possible with Itrazol?

Possible Side Effects and Safety Information

Itraconazole is associated with several safety risks detailed in governmental regulatory documents, including a BOXED WARNING regarding its effects on the heart.


Serious and Clinically Significant Risks

  • Congestive Heart Failure (CHF): Itraconazole has a negative inotropic effect and can cause or worsen CHF. It is contraindicated for the treatment of onychomycosis in patients with evidence of ventricular dysfunction or a history of CHF. If signs of heart failure occur, the medicine should be stopped.
  • Hepatotoxicity: Rare cases of serious, sometimes fatal, acute liver failure have been reported. Treatment must be discontinued immediately if signs or symptoms of liver disease (such as unusual fatigue, nausea, or dark urine) develop, and liver function should be tested.
  • Life-Threatening Drug Interactions: Due to its potential to inhibit the CYP3A4 enzyme, co-administration with numerous other medicines can lead to increased drug concentrations, resulting in life-threatening conditions like QT prolongation and Torsades de pointes (a serious cardiac arrhythmia).
  • Other Serious Events: These include reversible or permanent hearing loss, peripheral neuropathy (numbness or tingling), severe hypersensitivity reactions (e.g., Stevens-Johnson syndrome, anaphylaxis), and pseudoaldosteronism (worsening of hypertension and hypokalemia).

Common Adverse Reactions

The most commonly reported adverse reactions (ge 1%) in clinical trials affect several system-organ classes, primarily including the Gastrointestinal system (Nausea, Vomiting, Diarrhea, Abdominal pain), Nervous System (Headache, Dizziness), and General Disorders (Edema, Fatigue, Fever).

Population-Specific Safety Notes

Itraconazole is contraindicated for treating onychomycosis in pregnant women due to evidence of teratogenicity in animal studies. Women of childbearing potential must use effective contraception during and for two months following treatment. Patients with risk factors for CHF, pre-existing hepatic impairment, or those taking certain interacting medications require particular caution and monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected Itraconazole overdose, individuals must seek immediate medical attention and contact a poison control center or emergency room at once, as prompt action is officially mandated.

Manifestations Documented in Labeling Severe Outcomes and Risks
Signs consistent with Congestive Heart Failure (CHF), such as peripheral edema, orthopnea, or a rapid heartbeat Potential for Ventricular Tachyarrhythmias, including the life-threatening arrhythmia Torsades de Pointes
Gastrointestinal intolerance, including nausea, vomiting, abdominal pain, and headache Documented risk of fatal acute liver failure and a potent negative inotropic effect on the heart
Abnormal liver function test results Sustained high plasma concentrations

Emergency Management and Constraints:

Official regulatory information states clearly that no specific antidote is known for Itraconazole overdose. Therefore, management must focus on symptomatic and supportive measures. Due to the drug’s high lipophilicity and protein binding, it is not removed effectively by dialysis.

If signs of Congestive Heart Failure or serious hepatic injury occur during administration, the medication must be discontinued. Patients with renal failure are specifically noted as having an elevated risk for cardiac complications and require continuous observation.

Therapeutic Uses of Itrazol

What Itraconazole Treats: Main Uses and Benefits

Itraconazole is used for managing various types of fungal infections. This includes conditions such as systemic fungal infections (like histoplasmosis, blastomycosis, and aspergillosis), certain persistent skin and nail fungal infections (such as onychomycosis), and severe or recurrent candidiasis. The medication is often applied in clinical settings marked by heightened patient distress, helping to address groups of symptoms that may appear suddenly or intensify over time.

“Itraconazole is relevant in contexts marked by increased discomfort.”

In these scenarios, the medication provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. It helps address symptoms related to inflammatory or irritative states that create noticeable interference with daily comfort. This approach offers symptomatic relief, which may help patients cope more steadily with symptom fluctuations and difficult episodes.


Quick Fact: Supports in addressing symptoms related to physical discomfort


Regulatory References

  1. FDA-approved drug label on DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Itraconazole?

Itraconazole eligibility is defined by official regulatory criteria related to a patient’s medical history, age, and physiological state.

Absolute Contraindications

Itraconazole must not be used in individuals with known hypersensitivity to the drug or its components. It is also strictly contraindicated for treating non-life-threatening fungal infections, such as onychomycosis, in patients with existing Congestive Heart Failure (CHF) or a history of CHF. Use is contraindicated in pregnant women for any non-life-threatening indications.

Restricted and Conditional Use

Use is established in adult patients. However, the medicine is generally not recommended for pediatric patients because safety and efficacy have not been established. For both children and geriatric patients, use is advised only if the potential benefit clearly outweighs the potential risks, due to limited clinical data.

Special caution and monitoring are required for patients with hepatic impairment (liver issues) or renal impairment (kidney issues). Furthermore, due to the drug’s excretion into milk, use in nursing/breastfeeding mothers is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Itraconazole is defined by its role as a potent inhibitor of the CYP3A4 metabolic enzyme pathway, a function that significantly increases the plasma concentration of co-administered drugs metabolized by this route. This pharmacokinetic interaction necessitates numerous formal restrictions documented in government labeling.


Contraindicated Combinations

Co-administration with the following drug classes is strictly contraindicated due to the risk of serious adverse pharmacodynamic consequences, such as life-threatening cardiac events (QTc prolongation) or vasospasm (ergotism), resulting from dangerously increased exposure:

  • Antiarrhythmics: disopyramide, dofetilide, dronedarone, quinidine
  • HMG-CoA Reductase Inhibitors: lovastatin, simvastatin
  • Ergot Alkaloids: dihydroergotamine, ergometrine, ergotamine, methylergometrine

Exposure and Timing Constraints

Itraconazole's absorption is pH-dependent, which requires mandatory separation rules when co-administered with gastric acid-reducing agents. These agents (e.g., antacids, PPIs, H2-blockers) must be administered at least 2 hours before or 2 hours after the Itraconazole dose to prevent decreased exposure of the antifungal agent. Furthermore, the official label notes that overall drug exposure (AUC) is decreased in patients with moderate to severe renal impairment and that elimination half-life is doubled in subjects with hepatic impairment (cirrhosis), linking patient population to pharmacokinetic outcomes.

Mechanism of Action

How Itraconazole Works

Inhibition of Fungal Ergosterol Biosynthesis

Itraconazole exerts its primary effect by blocking the activity of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). The drug's triazole structure forms a coordinate bond with the enzyme's heme iron, effectively inhibiting a critical step in the pathway that synthesizes ergosterol, the essential membrane component required for the structural integrity of the fungal cell membrane.

Fungal Membrane Destabilization and Cellular Toxicity

The enzyme inhibition creates a dual cascade: the critical membrane component ergosterol is depleted, while cytotoxic intermediate 14-methylated sterols accumulate within the fungal cell. This combined defect compromises the fungal cell membrane's fluidity and permeability, leading to the functional failure of membrane-bound processes, ultimately resulting in the growth arrest (fungistatic) or death (fungicidal) of the fungal organism.

Sustained Activity via Active Metabolite

The overall physiological effect is sustained and significant by its primary active metabolite, hydroxyitraconazole. This metabolite targets the identical fungal CYP51 enzyme and contributes to the active, sustained blockade of ergosterol synthesis in the target environment.

Dosage and Administration Information

How to Use Itraconazole: Administration Guidelines

Itraconazole is primarily administered through the oral route as capsules, tablets, or an oral solution. The proper use of this antifungal medication is highly dependent on the formulation and the prescribed regimen, which is structured around guidance for optimal absorption.

Dosing and Timing Principles

Usage Aspect Administration Rule
Capsule/Tablet Intake Must be taken immediately after a full meal to maximize drug absorption, as the medication requires gastric acid to dissolve effectively.
Oral Solution Intake Must be taken without food (on an empty stomach). For oropharyngeal candidosis, the solution is typically swished in the mouth for approximately 20 seconds before swallowing.
Standard Dosing Systemic infections often require a loading dose, such as 200 mg three times daily for the first three days, followed by a maintenance dose of 200 mg once or twice daily.
Dose Division Total daily doses exceeding 200 mg are typically administered in two divided doses to enhance bioavailability.

Duration and Special Conditions

Treatment duration varies significantly by condition. Use for systemic fungal infections generally requires a prolonged course, often a minimum of three months, continuing until clinical stability is achieved. In contrast, specific conditions like onychomycosis may utilize an intermittent (pulse) regimen, consisting of one week of dosing separated by three drug-free weeks.

The capsule and oral solution are not bioequivalent and should not be substituted for one another unless under specialized guidance. For patients with low gastric acidity, capsules may be directed to be taken with an acidic beverage to aid in absorption. Dosing in older adults and those with hepatic or renal impairment requires careful consideration and potential dose adaptation.

Recent Clinical Evidence

Research evidence / Overview of studies for Itraconazole


Evidence for Systemic Fungal Infections

Itraconazole was studied for use in serious systemic fungal diseases, such as histoplasmosis, blastomycosis, and aspergillosis. Research examined these diseases and their progression over defined time intervals. The research included randomized controlled trials (RCTs), comparative studies, and meta-analyses that primarily monitored measurements related to patient outcomes and rates of clinical assessments in the observed populations.

The populations evaluated in this research consisted mainly of immunocompromised adults, such as those undergoing chemotherapy or organ transplants, and patients with active endemic fungal mycoses. Findings describe patterns observed in these studies, where researchers recorded clinical outcome measurements and measurements of pathogen clearance. Data show patterns related to significant variability in systemic drug exposure (pharmacokinetics) across patients, particularly when using the capsule formulation. Studies also monitored adverse event and study withdrawal measurements.


Evidence for Superficial Fungal Infections (Skin and Nails)

Research has also explored the use of Itraconazole for superficial fungal infections, such as onychomycosis (nail fungus) and mucosal candidiasis. The research involves controlled trials that compare different dosing schedules, such as continuous dosing versus pulse dosing, and other antifungal treatments.

Studies focused on outcomes related to physical discomfort and cosmetic appearance. The main measurements recorded were measurements of mycological assessment and measurements of clinical change, which reflects the visible change in the nail. Research highlights changes measured during the study period, and the long follow-up times was observed in studies to allow for complete nail growth before final outcome assessments were described.


Long-Term Research and Durability of Findings

A key consideration across all indications is the length of time patients was observed in the research. For severe systemic infections, long-term effects are not fully established, meaning long-term patient outcomes or the rates of infection recurrence, is still uncertain. Similarly, for onychomycosis, follow-up durations were limited in many trials, which means that long-term recurrence measurements and the specific rates of recurrence over extended follow-up are not fully established.


Areas of Uncertainty and Research Gaps

Despite the existing body of evidence, research limitation frames mean that the certainty remains low in specific areas. These limitations include the observation that sample sizes were modest in some pivotal trials, the variability across studies, and the issue of inconsistent oral absorption was observed in some studies for some formulations. Finally, comparative evidence is lacking for certain new treatment approaches.

Key Studies & References

  1. Oral treatments for toenail onychomycosis: a systematic review (Cochrane Review/Evidence of long follow-up times and comparative data)
  2. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection (Evidence of safety outcomes/discontinuation)

Frequently Asked Questions (FAQ)

Common questions about Itraconazole (FAQ)


Q: Is Itraconazole effective against all types of fungal infections, or only specific ones?

A: Official documents state that Itraconazole is indicated for treating specific fungal infections. These include serious internal infections like blastomycosis, histoplasmosis, and aspergillosis, as well as superficial infections like onychomycosis (nail fungus). It is not indicated for every type of fungal infection.

Q: Can Itraconazole be used to prevent fungal infections in certain patient populations?

A: Studies and official clinical guidelines indicate that Itraconazole is recommended for the primary and secondary prevention, known as prophylaxis, of certain fungal infections. This use is generally reserved for specific patient groups, such as those with weakened immune systems.

Q: What happens to the effectiveness of Itraconazole if the capsules are taken on an empty stomach?

A: Regulatory pharmacokinetic information indicates that the absorption of the capsule formulation is significantly reduced if it is not taken with food. The drug requires the presence of gastric acid (stomach acid) to dissolve and be absorbed effectively into the bloodstream.

Q: What does the term 'peripheral neuropathy' mean in relation to Itraconazole side effects?

A: Peripheral neuropathy is a possible serious adverse event listed in the official drug labels. This condition involves the nerves outside the brain and spinal cord, often resulting in sensations of numbness or tingling in the extremities. Official warnings advise that a healthcare professional should be contacted immediately if symptoms of this condition develop.

Q: What are the signs of a severe allergic reaction to Itraconazole?

A: The symptoms of a severe allergic reaction, or hypersensitivity, can be life-threatening. These signs can include swelling of the face, lips, or tongue, difficulty breathing, shortness of breath, or a widespread rash, itching, or hives on the skin.

Q: Is it necessary to monitor blood levels of Itraconazole during long-term therapy?

A: Due to significant patient-to-patient variability in drug exposure and its non-linear absorption, Therapeutic Drug Monitoring (TDM) may be recommended in certain clinical situations. This monitoring is intended to measure the concentration of the medicine in the blood to help ensure appropriate levels are maintained.

Q: How long does the drug stay in the body's tissues after the patient stops taking it?

A: Itraconazole and its active metabolite have a high affinity for keratinous tissues, such as skin and nails, allowing the drug to persist for a long time after the final dose. The elimination half-life is described as increasing to approximately 34 to 42 hours with repeated dosing.

Q: Is Itraconazole contraindicated for people with a history of kidney disease?

A: Itraconazole is generally not an absolute contraindication for kidney disease. However, the official product information indicates that close monitoring and potential dose adaptation may be necessary for patients with renal (kidney) impairment.

Q: Is it common for patients to experience hair thinning or loss when using Itraconazole?

A: Hair loss (alopecia) or hair thinning is reported as an adverse reaction associated with Itraconazole. Regulatory documentation typically categorizes this as a rare event.

Q: Can taking Itraconazole affect the effectiveness of hormonal birth control?

A: Itraconazole can affect how other drugs are processed in the body due to its interaction with the CYP3A4 enzyme. Regulatory and clinical references mention isolated reports of breakthrough bleeding and unintended pregnancy, suggesting that the effectiveness of oral contraceptives may be altered.

Q: Why is concurrent use with certain benzodiazepines strongly discouraged?

A: The official drug label explicitly contraindicates co-administration with certain benzodiazepines, such as alprazolam. This prohibition is due to the potential for dangerously increased concentrations of the benzodiazepine, which can lead to toxicity and severe central nervous system depression.

Q: What happens when Itraconazole is combined with alcohol?

A: Patient information materials provided by health authorities typically state that alcohol should be avoided while undergoing treatment with Itraconazole. This is a standard precaution often related to managing the potential for increased risk of side effects, such as those affecting the liver.

Q: Are there any common over-the-counter supplements or herbal remedies that should be avoided?

A: Official labels recommend that a healthcare provider is informed about all substances being used, including over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and other supplements. This is because many products can affect the drug's levels in the body, which requires professional evaluation.

Q: Is Itraconazole typically used to treat common conditions like athlete's foot?

A: Itraconazole has been studied and used for the treatment of tinea pedis (athlete's foot), which is a type of superficial fungal infection. The decision on its use is determined by the severity of the condition and the specific pathogen identified.

Q: Is it normal for a rash to develop as a non-serious side effect of Itraconazole?

A: Clinical trial data shows that rash and itching are reported as common side effects of the medication. Regulatory information indicates that rash occurred in a noticeable percentage of patients during studies.

Q: Are vision changes, such as blurred vision, a recognized side effect of Itraconazole?

A: Official patient information advises that certain changes to the nervous system and vision can occur. These recognized effects include dizziness and temporary blurred or double vision.

Q: Is Itraconazole an appropriate treatment choice for all fungal infections in the fingernails and toenails?

A: The capsule formulation is officially indicated for the treatment of onychomycosis (nail fungal infection) that is specifically caused by dermatophytes. Therefore, it is indicated for a certain class of pathogens and may not be appropriate for all types of fungi that can infect the nail.

Q: Does Itraconazole interact with widely used over-the-counter painkillers?

A: According to official interaction data, no interaction has been found between Itraconazole and common over-the-counter painkillers, such as ibuprofen. This indicates that co-administration does not typically lead to a change in the concentration of either drug.

How should Itrazol be stored and disposed of?

Storage and Disposal of Itraconazole

The official labeling dictates specific storage rules for itraconazole formulations to maintain stability and integrity.


Storage Requirements

Formulation Temperature Requirement Environmental Protection
Capsules Store at controlled room temperature (15 C to 25 C). Protect from light and moisture.
Oral Solution Store at or below 25 C. Do not freeze and protect from light.

Both the capsules and the oral solution must be kept in the original container, sealed tightly, and stored out of the reach of children. The product should not be used if the original seal is damaged.


Disposal Instructions

Unused or expired itraconazole must be discarded safely. Health authorities recommend using a drug take-back location or a mail-back program as the primary method. If these are unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt) and sealed in a container before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itrazol found in:

A-Z Index: